A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine

Trial Profile

A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacogenomic; Registrational
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 26 Mar 2014 Trial status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
    • 14 Apr 2013 Accrual to date is 102% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top